Previous 10 | Next 10 |
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results ...
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...
2024-01-17 12:48:13 ET More on INVO BioScience Invo to acquire Naya Biosciences in all-stock deal Seeking Alpha’s Quant Rating on INVO BioScience Historical earnings data for INVO BioScience Financial information for INVO BioScience For further...
2024-01-11 13:08:57 ET More on Atreca, Sera Prognostics, etc. Sera Prognostics: The Pregnancy Company On A Hot Streak Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more Sera P...
2024-01-09 14:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025 STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the ...
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offer...
2024-01-05 06:29:15 ET More on Kymera Therapeutics Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases Kymera stock dips 5% following BofA downgrade Seeking Alpha’s Quant Rating on Kymera Therapeutics Historical e...
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering ...
2024-01-04 18:28:07 ET More on Kymera Therapeutics Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript Kymera stock dips 5% following BofA downgrade Seeki...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
2024-05-02 14:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 202...